Chest:慢性阻塞性肺病患者慢性咳嗽的临床意义

2020-01-28 xing.T MedSci原创

由此可见,就较多的呼吸道症状和医疗保健使用情况,较低的肺功能和较高炎症水平来看,COPD患者合并慢性咳嗽会导致更严重的病情。

咳嗽在COPD患者中的作用和影响尚未在一般人群中进行描述。近日,呼吸领域权威杂志chest上发表了一篇研究文章,研究人员假设慢性咳嗽是COPD患者疾病严重程度的标志。

研究人员从哥本哈根总人群研究中确定了43271名成年人的嵌套队列,鉴定出患有COPD和慢性咳嗽的受试者,并记录了呼吸系统症状、医疗保健利用情况、肺功能和血液中的炎症生物标记物。

在来自总人群的43271名受试者中,有8181人(19%)患有COPD,其中796人(10%)有慢性咳嗽。COPD合并慢性咳嗽的受试者的Leicester咳嗽问卷总分中位数为17.7(25-75%:16.0-18.9),对应于身体部分为5.9(5.3-6.3),心理部分为5.6(4.9-6.3) ,以及社交部分为6.3(5.8-6.8)。在COPD患者中,慢性咳嗽患者与无咳嗽患者相比,有痰(60% vs. 8%)、喘息(46% vs. 14%)、呼吸困难(66% vs. 38%)、胸痛/胸闷(9% vs. 4%)、夜间呼吸困难(8% vs. 3%)、近10年的急性支气管炎/肺炎发作(45% vs. 25%)以及过去12个月的全科医生就诊(53% vs. 37%)的几率更高。此外,这些人的FEV1%预测值(81% vs. 89%)和FEV1/FVC(0.64对0.66)较低,以及高敏C反应蛋白、纤维蛋白原、白细胞、中性粒细胞、嗜酸性粒细胞和IgE水平较高。

由此可见,就较多的呼吸道症状和医疗保健使用情况,较低的肺功能和较高炎症水平来看,COPD患者合并慢性咳嗽会导致更严重的病情。

原始出处:

Eskild Landt,et al.Chronic cough in individuals with COPD: a population-based cohort study.chest.2020.https://doi.org/10.1016/j.chest.2019.12.038

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696918, encodeId=d1ca169691824, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Oct 29 02:13:00 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051501, encodeId=af9f205150107, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Apr 17 11:13:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929612, encodeId=5b731929612db, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Aug 03 21:13:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671943, encodeId=68ab16e1943ea, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Jul 19 12:13:00 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-10-29 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696918, encodeId=d1ca169691824, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Oct 29 02:13:00 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051501, encodeId=af9f205150107, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Apr 17 11:13:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929612, encodeId=5b731929612db, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Aug 03 21:13:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671943, encodeId=68ab16e1943ea, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Jul 19 12:13:00 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696918, encodeId=d1ca169691824, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Oct 29 02:13:00 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051501, encodeId=af9f205150107, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Apr 17 11:13:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929612, encodeId=5b731929612db, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Aug 03 21:13:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671943, encodeId=68ab16e1943ea, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Jul 19 12:13:00 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-08-03 Smile2680
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696918, encodeId=d1ca169691824, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Oct 29 02:13:00 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051501, encodeId=af9f205150107, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Apr 17 11:13:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929612, encodeId=5b731929612db, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Mon Aug 03 21:13:00 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671943, encodeId=68ab16e1943ea, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Jul 19 12:13:00 CST 2020, time=2020-07-19, status=1, ipAttribution=)]
    2020-07-19 amy0559

相关资讯

JAMA:FEV1/FVC与COPD相关不良事件风险

研究认为,将气流阻塞定义为FEV1/FVC低于0.70是临床中诊断COPD准确依据,可显著降低相关疾病的不良预后风险

维罗纳制药的COPD药物恩替芬碱获得另一项欧盟专利

欧洲专利局已授予维罗纳制药公司的慢性阻塞性肺病(COPD)药物恩替芬碱(RPL554)的另一项关键专利。相应的专利已在美国发布。

维罗纳制药使用干粉吸入的恩替芬碱治疗慢性阻塞性肺病II期临床结果喜人

维罗纳制药公司的恩替芬碱干粉吸入器(DPI)配方用于慢性阻塞性肺病(COPD)的维持治疗的II期临床试验,达到了所有初级和次级肺功能终点。

BMJ:慢性阻塞性肺病患者预后预测模型

本研究对COPD患者预后模型进行了详细评估。调查结果表明,大部分在发展过程中存在若干方法上的缺陷,外部验证率较低

Chest:慢性阻塞性肺病患者骨质疏松症患病率和危险因素

骨质疏松症在COPD个体中普遍存在,并且在许多国家中患病率似乎很高且相似。应对COPD患者进行骨质疏松症和危险因素的筛查。

2019 SATS立场声明:慢性阻塞性肺疾病的管理(更新版)

简要介绍:2019年11月,南非胸科学会(SATS)更新发布了慢性阻塞性肺疾病的管理声明,慢性阻塞性肺疾病(COPD)是导致,发展中国家致残和死亡的重要原因。本文是南非胸科学会(SATS)对2012年版慢性阻塞性肺疾病的管理指南的更新。